Actively Recruiting

Phase 2
Age: 30Years +
All Genders
NCT05266417

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Led by Gateway Institute for Brain Research · Updated on 2026-03-31

56

Participants Needed

2

Research Sites

285 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

CONDITIONS

Official Title

Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

Who Can Participate

Age: 30Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Documented clinical diagnosis of idiopathic Parkinson's Disease
  • Able to administer study drug or have a caregiver to assist throughout the study
  • Willing to consistently continue baseline diet, exercise, and medications during the trial
  • Stable dose of Parkinson's medications or nutraceuticals for at least 30 days before screening
  • Stable dose of chronic antidepressant or anxiolytic for at least 90 days before screening
Not Eligible

You will not qualify if you...

  • Diagnosis of Type 1 or Type 2 Diabetes Mellitus
  • Glycated hemoglobin (HbA1c) level 6.5% or higher
  • History of symptomatic hypoglycemia or documented low plasma glucose with symptoms
  • Mini-Mental State Exam score 24 or lower at screening
  • Positive COVID-19 test at or within 30 days before screening
  • Recent change or increase in dose of chronic cognitive-impairing therapies within 8 weeks before screening or during study
  • Chronic nasal inflammation or history of recurrent nosebleeds or uncontrolled allergic rhinitis
  • Poorly controlled respiratory diseases such as asthma or COPD
  • History of significant neurological or psychiatric diseases other than Parkinson's Disease
  • Current epilepsy diagnosis with recent seizures or unexplained loss of consciousness
  • History of stroke with residual neurological deficits
  • Unstable or uncontrolled heart disease posing safety risks
  • Use of insulin or other anti-hyperglycemic agents except isolated gestational diabetes
  • Use of glutathione supplements or medications that increase glutathione levels

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Institute for Neuroimmune Medicine

Davie, Florida, United States, 33314

Actively Recruiting

2

Las Mercedes Medical Research

Hialeah, Florida, United States, 33012

Actively Recruiting

Loading map...

Research Team

S

Susana Restrepo, PhD

CONTACT

V

Vanesa Javier

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here